AVB-114 Demonstrates Clinical Benefit in Persistent Crohn’s Perianal Fistulas: Randomized Cohort Results from the Multicenter STOMP2 Trial

20260 citationsJournal Article

Authors

David A. Schwartz · Vanderbilt University Medical Center

Eric Dozois · Mayo Clinic

Eric C. Ehman · Mayo Clinic in Arizona

W Faubion · Mayo Clinic Hospital

David Hudesman · NYU Langone Health

Todd A. Johnson · Department of Biological Sciences

Baldeep Pabla ·

Abstract

A significantly higher proportion of patients treated with AVB-114 achieved combined remission versus SoC, and the treatment was well tolerated. These data support the safety and efficacy of AVB-114 in persistent Crohn's perianal fistulas.

Topics & Keywords

Inflammatory Bowel Disease Anorectal Disease Treatments and Outcomes Autoimmune and Inflammatory Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The American Journal of Gastroenterology

DOI: 10.14309/ajg.0000000000004005

Field-Weighted Citation Impact: 0.00